ELVN Enliven Therapeutics Inc
Price (delayed)
$22.33
Market cap
$1.05B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.92
Enterprise value
$957.88M
Highlights
Enliven Therapeutics's EPS has surged by 74% YoY
The company's quick ratio has shrunk by 53% YoY but it rose by 10% QoQ
ELVN's equity is up by 9% YoY but it is down by 4% QoQ
The company's net income has shrunk by 61% YoY and by 4.1% QoQ
Key stats
What are the main financial stats of ELVN
Market
Valuations
Earnings
Shares outstanding
47.24M
Market cap
$1.05B
Enterprise value
$957.88M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.44
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$82.6M
EBITDA
-$81.82M
Free cash flow
-$72.22M
Per share
Balance sheet
Liquidity
EPS
-$1.92
Free cash flow per share
-$1.5
Book value per share
$6.48
Revenue per share
$0
TBVPS
$6.8
Total assets
$327.04M
Total liabilities
$22.11M
Debt
$0
Equity
$304.93M
Working capital
$296.02M
Debt to equity
0
Current ratio
14.39
Quick ratio
14.13
Net debt/EBITDA
1.18
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-27.3%
Return on equity
-29.3%
Return on invested capital
-46.5%
Return on capital employed
-27.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ELVN stock price
How has the Enliven Therapeutics stock price performed over time
Intraday
-3.21%
1 week
1.92%
1 month
4.74%
1 year
35.58%
YTD
61.34%
QTD
-4.45%
Financial performance
How have Enliven Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$97.57M
Net income
-$82.83M
Gross margin
N/A
Net margin
N/A
Enliven Therapeutics's operating income has shrunk by 69% YoY and by 4.8% QoQ
The company's net income has shrunk by 61% YoY and by 4.1% QoQ
Growth
What is Enliven Therapeutics's growth rate over time
Valuation
What is Enliven Therapeutics stock price valuation
P/E
N/A
P/B
3.44
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Enliven Therapeutics's EPS has surged by 74% YoY
ELVN's P/B is 55% above its 5-year quarterly average of 2.3 and 37% above its last 4 quarters average of 2.6
ELVN's equity is up by 9% YoY but it is down by 4% QoQ
Efficiency
How efficient is Enliven Therapeutics business performance
ELVN's return on invested capital has surged by 64% year-on-year and by 4.1% since the previous quarter
The return on equity is up by 22% year-on-year
Enliven Therapeutics's ROA has increased by 2.8% YoY
Dividends
What is ELVN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ELVN.
Financial health
How did Enliven Therapeutics financials performed over time
ELVN's total liabilities has soared by 133% year-on-year but it is down by 12% since the previous quarter
The current ratio has plunged by 54% YoY but it has grown by 7% from the previous quarter
The debt is 100% less than the equity
ELVN's equity is up by 9% YoY but it is down by 4% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.